Bioniz, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Bioniz, LLC - overview
Established
2010
Location
Irvine, CA, US
Primary Industry
Biotechnology
About
Bioniz, LLC specializes in developing innovative therapeutic solutions, utilizing a proprietary technology platform to address unmet medical needs in autoimmune diseases and chronic conditions through advanced biopharmaceutical products. Bioniz, LLC, founded in 2010 and headquartered in Irvine, US, focuses on therapeutic solutions for autoimmune diseases and inflammation. The company has executed a total of 6 deals, with the most recent funding round being VENTURE DEBT of USD 8. 000 mn, contributing to a total amount raised of USD 15.
550 mn. The company was acquired by Equillium, Inc. in February 2022, further enhancing its pipeline of immunomodulatory drug candidates. Nazli Azimi serves as both the CEO and founder of the company.
Bioniz focuses on developing innovative therapeutic solutions leveraging its proprietary technology platform. Its core offerings include advanced biopharmaceutical solutions targeting significant unmet medical needs in autoimmune diseases, inflammation, and chronic conditions. Their flagship product is designed to modulate the immune system for conditions traditionally lacking effective management options, serving clients such as healthcare providers and specialty clinics across North America and Europe. Bioniz operates a revenue model based on direct sales to healthcare providers and partnerships with pharmaceutical wholesalers.
Their transaction structure revolves around product sales, with potential subscription-based models for ongoing therapies. Pricing plans are tailored to various healthcare environments, reflecting the therapeutic value of their products, to enhance accessibility for healthcare institutions. Following the acquisition by Equillium, Inc. in February 2022, Bioniz aims to expand its portfolio with new immunomodulatory drug candidates.
The company plans to leverage recent funding to accelerate the development of additional products and expand into new markets, focusing on regions with growing demand for novel therapeutic interventions. Specific geographic targets are currently being identified as they strategize their approach to market expansion.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.bioniz.com
Total Amount Raised
Subscriber access only
Bioniz, LLC - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.